Biology:ENTPD1

From HandWiki
Short description: Mammalian protein found in Homo sapiens


A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example

Ectonucleoside triphosphate diphosphohydrolase-1 (gene: ENTPD1; protein: NTPDase1) also known as CD39 (Cluster of Differentiation 39), is a typical cell surface enzyme with a catalytic site on the extracellular face.[1][2][3]

Function

NTPDase1 is an ectonucleotidase that catalyse the hydrolysis of γ- and β-phosphate residues of triphospho- and diphosphonucleosides to the monophosphonucleoside derivative.[4][5] NTPDase1 hydrolyzes P2 receptor ligands, namely ATP, ADP, UTP and UDP with similar efficacy.[6] NTPDase1 can therefore affect P2 receptor activation and functions.[7]

Clinical significance

ATP causes a pro-inflammatory environment, whereas degradation of ATP into adenosine by the CD39/CD73 pathway leads to an anti-inflammatory environment.[8] CD39 converts ATP (or ADP) to adenosine monophosphate (AMP), which is converted into adenosine by CD73.[8][9] A substantial portion of the immune suppressive and anti-inflammatory activity of regulatory T cells (Tregs) is due to the adenosine produced by the CD39/CD73 pathway, insofar as Tregs express CD39 and CD73.[8] [9]

Adenosine produced by the CD39/CD73 pathway can protect against ischemia-reperfusion injury.[8] On the other hand, high expression and activity of CD39 and CD73 on cancer cells can prevent the immune system from inhibiting the progression of cancer.[8]

Biallelic pathogenic variant in ENTPD1 causes autosomal recessive spastic paraplegia 64 (SPG64).[10][11] SPG64 is a complex hereditary spastic paraplegia characterized by childhood onset progressive spastic paraparesis, delayed developmental milestones, intellectual disability, dysarthria, and white matter abnormalities.

See also

References

  1. "Entrez Gene: ENTPD1 Ectonucleoside triphosphate diphosphohydrolase 1". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=953. 
  2. "Purification of the blood vessel ATP diphosphohydrolase, identification and localisation by immunological techniques". Biochimica et Biophysica Acta (BBA) - General Subjects 1334 (1): 73–88. Feb 1997. doi:10.1016/s0304-4165(96)00079-7. PMID 9042368. 
  3. "Identification and characterization of CD39/vascular ATP diphosphohydrolase". The Journal of Biological Chemistry 271 (51): 33116–22. Dec 1996. doi:10.1074/jbc.271.51.33116. PMID 8955160. 
  4. "The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance". Purinergic Signalling 2 (2): 409–30. Jun 2006. doi:10.1007/s11302-006-9003-5. PMID 18404480. 
  5. "Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1783 (5): 673–94. May 2008. doi:10.1016/j.bbamcr.2008.01.024. PMID 18302942. 
  6. "Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8". Purinergic Signalling 1 (2): 193–204. Jun 2005. doi:10.1007/s11302-005-6217-x. PMID 18404504. 
  7. "Impact of ectoenzymes on p2 and p1 receptor signaling". Pharmacology of Purine and Pyrimidine Receptors. Advances in Pharmacology. 61. 2011-01-01. pp. 263–99. doi:10.1016/B978-0-12-385526-8.00009-6. ISBN 9780123855268. 
  8. 8.0 8.1 8.2 8.3 8.4 "CD39 and CD73 in immunity and inflammation". Trends in Molecular Medicine 19 (6): 355–367. 2013. doi:10.1016/j.molmed.2013.03.005. PMID 23601906. 
  9. 9.0 9.1 "Role of adenosine A2b receptor overexpression in tumor progression". Life Sciences 166: 92–99. 2016. doi:10.1016/j.lfs.2016.10.008. PMID 27729268. 
  10. "Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders". Science 343 (6170): 506–511. Jan 2014. doi:10.1126/science.1247363. PMID 24482476. 
  11. "Biallelic Variants in the Ectonucleotidase ENTPD1 Cause a Complex Neurodevelopmental Disorder with Intellectual Disability, Distinct White Matter Abnormalities, and Spastic Paraplegia". Ann Neurol 92 (2): 304–321. Aug 2022. doi:10.1002/ana.26381. PMID 35471564. 

Further reading

External links